| High Risk Neuroblastoma studied in …STUDIED_INderived18 of 18show fewer |
|---|
| → studied in | NCT07537400Phase 2 · recruiting Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06858501Phase 2 · withdrawn Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06528496Phase 2 · recruiting N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05650749Phase 1 · enrolling by invitation GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06057948Phase 2 · recruiting A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07688252Phase 1 · not yet recruiting Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07007117Phase 1 · active not recruiting PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04751383Phase 1 · terminated Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05130255Phase 1 · terminated GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06607692Phase 1/Phase 2 · recruiting Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03786783Phase 2 · completed Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502287Phase 1/Phase 2 · recruiting Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03794349Phase 2 · active not recruiting Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06831552NA · recruiting Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06803875Phase 1/Phase 2 · recruiting Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06182410Phase 2 · withdrawn Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06335745NA · withdrawn PediCARE Health Equity Intervention in High-Risk Neuroblastoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02771743Phase 2 · unknown Response-based Treatment of High-risk Neuroblastoma · condition mapped CURATED_BROADER · 18 trials mapped (11 active) | — | — | High Risk Neuroblastoma | 1 | Observed | clinicaltrials | graph → |